Novo CSO welcomes rival's success
In recent studies, Eli Lilly showed promising data for two candidates that are to ensure the US drug group success at the crucial GLP-1 market. CSO in Novo Nordisk, Mads Krogsgaard Thomsen, also consider the rival's results a positive development for the Danish drug group. "A happy and innovative competitor is the best," he says and stresses that Novo can still make a countermove.
In the past month, US drug group Eli Lilly has showed positive data from two clinical trials with diabetes drugs. The results might influence the rival Novo Nordisk's future opportunities in the most critical segment of the diabetes market: treatment of type 2 diabetes with GLP-1-based medicines.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
